Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar with concurrent chemoradiotherapy in cervical squamous cell cancer
ChiCTR-IPR-17011374Phase 4Recruiting
- Sponsor
- Gansu Cancer Hospital
- Start
- May 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of endostar in Cervical Cancer (CC), cervical squamous cell carcinoma (CSCC) and cervical adenocarcinoma (2 arms), sponsored by Gansu Cancer Hospital. Primary endpoints: Objective response rate, Progression-free survival and 2 more. Started May 2017; status: recruiting.
02
Drugs
endostar
03
Conditions
Cervical Cancer (CC)cervical squamous cell carcinoma (CSCC)cervical adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-IPR-17011374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011374.